Treatment of human RCC cell lines with adiponectin inhibits two essential steps in the metastatic process: the secretion of VEGF and the MMP-2- and MMP-9-dependent invasion and migration, leading to a decrease in the angiogenic capacity of human RCC cells [94]. Here, ADIPOQ is linked to renal cell carcinoma.